Business Context and Reporting Period
This Form 8-K Current Report was filed by CorMedix Inc. on May 11, 2020. The filing primarily addresses the appointment of Dr. Matt David as Executive Vice President and Chief Financial Officer, effective May 11, 2020. The Company is a biopharmaceutical entity focused on developing treatments, including the product Neutrolin.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
- Annual Base Salary: $330,000
- Annual Bonus Target: Up to 30% of base salary
- Initial Equity Grant: 250,000 stock options
- Option Exercise Price: $5.63 per share or Fair Market Value on grant date, whichever is higher
Material Changes
The material change reported is the addition of Dr. Matt David to the executive team. He joins from Ovid Therapeutics Inc., where he served as Head of Strategy. His background includes investment banking roles at Bank of America Merrill Lynch, Piper Jaffray, and Thomas Weisel Partners, as well as clinical experience as a surgical resident.
Guidance, Outlook, and Compensation Terms
The filing details the terms of Dr. David's three-year employment agreement, with automatic one-year renewals unless terminated with notice.
- Equity Vesting: 166,000 options vest over four years (Time Options); 84,000 options vest based on performance milestones (Milestone Options).
- Termination for Cause: Results in forfeiture of all unvested equity awards granted on or after the effective date.
- Termination without Cause/Good Reason: Entitles Dr. David to 9 months of base salary, prorated bonus, COBRA premium payments, and acceleration of certain equity vesting.
- Corporate Transaction: Triggers full vesting of all equity awards and options.
- Non-Compete: Dr. David is prohibited from engaging in competing anti-infective product development for 12 months post-employment.
The filing does not contain financial guidance, market outlook, or specific risk factors beyond standard employment agreement contingencies.
Investor Verification Checklist
- Verify the current stock price to determine the final exercise price of the 250,000 options granted (capped at $5.63 or Fair Market Value).
- Review the upcoming Form 10-Q for the quarter ending June 30, 2020, for the full text of the employment agreement.
- Monitor future filings for the definition of "performance milestones" attached to the 84,000 Milestone Options.
- Assess the impact of the new CFO's background on the Company's capital raising strategy and investor relations.